Evogene (NASDAQ:EVGN) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Evogene Ltd. (NASDAQ:EVGN)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.87 and traded as low as $1.36. Evogene shares last traded at $1.38, with a volume of 35,602 shares.

Wall Street Analyst Weigh In

EVGN has been the topic of several research reports. StockNews.com initiated coverage on shares of Evogene in a report on Wednesday. They issued a “sell” rating on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Trading Down 1.1 %

The firm has a market cap of $7.38 million, a price-to-earnings ratio of -0.31 and a beta of 1.28. The company has a fifty day moving average price of $1.50 and a 200-day moving average price of $1.87.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. The company had revenue of $1.61 million during the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same period in the previous year, the company posted ($1.30) earnings per share.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.40% of Evogene as of its most recent SEC filing. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.